SCIDENTIFY

1:10,000 families lose a parent each year to acute myeloid leukemia. Why? Because the relapse rate is over 50%. SCIDENTIFY aims to help irradicate AML by greatly improving the minimal residual disease detection limit and thereby aid clinicians with their treatment plan.
Our technology is a cloud-native software suite that looks at R&D and diagnostics data from an existing device (mass cytometer) with a completely new angle. It offers the ability to detect cell abnormality with unprecedented precision and hence to distinguish malign from healthy cells. We call it spatial mass cytometry.